Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC
- PMID: 20029441
- DOI: 10.1038/nrclinonc.2009.173
Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC
Abstract
Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-alpha as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer.
Comment on
-
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1. J Clin Oncol. 2009. PMID: 19487381 Free PMC article. Clinical Trial.
Similar articles
-
Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.Ann Oncol. 2016 Jan;27(1):159-65. doi: 10.1093/annonc/mdv504. Epub 2015 Oct 21. Ann Oncol. 2016. PMID: 26489444 Free PMC article.
-
Commentary on "Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α." Tsimafeyeu I, Zart JS, Chung B, Kidney Cancer Research Bureau, Moscow, Russian Federation.: BJU Int 2013; 112(1):32-8. [Epub 2013 Jun 7]. doi: 10.1111/bju.12107.Urol Oncol. 2014 May;32(4):514-5. doi: 10.1016/j.urolonc.2013.12.011. Urol Oncol. 2014. PMID: 24767689
-
Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.BJU Int. 2012 May;109(9):1349-54. doi: 10.1111/j.1464-410X.2011.10534.x. Epub 2011 Aug 25. BJU Int. 2012. PMID: 21883864
-
New treatment approaches in renal cell carcinoma.Anticancer Drugs. 2009 Nov;20(10):893-900. doi: 10.1097/CAD.0b013e32833123d4. Anticancer Drugs. 2009. PMID: 19752718 Review.
-
Update on systemic therapies of metastatic renal cell carcinoma.World J Urol. 2010 Jun;28(3):303-9. doi: 10.1007/s00345-010-0519-5. Epub 2010 Feb 24. World J Urol. 2010. PMID: 20180125 Review.
Cited by
-
The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility.Curr Urol Rep. 2017 Aug;18(8):65. doi: 10.1007/s11934-017-0704-9. Curr Urol Rep. 2017. PMID: 28712040 Review.
-
Chronic inflammation and immunologic-based constraints in malignant disease.Immunotherapy. 2011 Oct;3(10):1265-74. doi: 10.2217/imt.11.113. Immunotherapy. 2011. PMID: 21995576 Free PMC article. Review.
-
A comprehensive overview of targeted therapy in metastatic renal cell carcinoma.Curr Cancer Drug Targets. 2012 Sep;12(7):857-72. doi: 10.2174/156800912802429265. Curr Cancer Drug Targets. 2012. PMID: 22515521 Free PMC article. Review.
-
Systemic therapy in hepatocellular carcinoma.Clin Liver Dis. 2011 May;15(2):423-41, vii-x. doi: 10.1016/j.cld.2011.03.002. Clin Liver Dis. 2011. PMID: 21689622 Free PMC article. Review.
-
Systemic therapies for metastatic renal cell carcinoma in the second-line setting: A systematic review and network meta-analysis.Medicine (Baltimore). 2022 Sep 16;101(37):e30333. doi: 10.1097/MD.0000000000030333. Medicine (Baltimore). 2022. PMID: 36123840 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources